Last updated: February 22, 2026
What is NDC 62135-0883?
NDC 62135-0883 is a prescription drug identified by the National Drug Code (NDC). The specific drug is Tecentriq (atezolizumab), 1200 mg IV powder for reconstitution. This immunotherapy targets PD-L1 and is used primarily in treating urothelial carcinoma, small cell lung cancer, and triple-negative breast cancer.
Market Overview
Market Size and Growth
The global oncology immunotherapy market was valued at approximately USD 123 billion in 2022 and projected to grow at a CAGR of 12.4% through 2030 (source: MarketsandMarkets). Tecentriq holds a significant share within this market, especially in lung and breast cancer segments.
Key Competitors
| Drug Name |
Indication |
Approval Date |
Market Share (2022) |
Price (USD per dose) |
| Tecentriq |
NSCLC, UC, TNBC |
2016, 2019, 2019 |
~25% in immunotherapy segment |
$11,350 per 1200 mg dose |
| Keytruda |
Multiple, including NSCLC, melanoma |
2014 |
~40% |
$12,500 per 200 mg dose |
| Imfinzi |
NSCLC, SCLC |
2018 |
~15% |
$9,500 per 500 mg dose |
Note: Prices reflect direct list prices; actual reimbursements are often lower.
Dosage and Treatment Regimen
The standard dose of Tecentriq for approved indications is 1200 mg intravenously every three weeks. The drug is administered in outpatient settings. Patients often receive multiple cycles, leading to increased cumulative costs over treatment duration.
Current Pricing and Market Position
Price Points
- USD 11,350 per 1200 mg dose (list price).
- Average annual treatment costs for Tecentriq range from USD 70,000 to USD 130,000, depending on treatment length and combination therapy.
Reimbursement Landscape
Coverage depends on payer policies, clinical guidelines, and regional regulations. In the U.S., Medicare and private insurers generally reimburse Tecentriq at or near list prices, subject to negotiated discounts.
Price Trends (2018–2023)
| Year |
Average Price per Dose (USD) |
Notes |
| 2018 |
$11,150 |
Initial launch pricing. |
| 2020 |
$11,350 |
Slight price increase, inflation-adjusted. |
| 2023 |
$11,350 |
Stable, barring policy changes. |
No significant price reductions have occurred to date, although discounts and rebates are common in actual transactions.
Projected Market and Price Trends
Short-Term (1–2 years)
- Stabilization of list prices.
- Increasing adoption due to expanded indications.
- Entry of biosimilars unlikely within this period.
Medium to Long-Term (3–5 years)
- Possible price erosion driven by volume increases and payer negotiations.
- Market saturation limits major price reductions.
- Potential introduction of biosimilars or competitors could pressure prices downward by 10–20%.
Impact of Biosimilars
Currently, no biosimilars for atezolizumab are approved in the U.S., but biosimilar development is ongoing. When introduced, biosimilars could reduce Tecentriq's price by approximately 20%–30%, aligning with trends seen in other monoclonal antibodies.
Regulatory and Policy Influences
- Cost-containment policies and value-based pricing models may impact future list prices.
- Global pricing varies due to different healthcare systems and patent protections.
Market Challenges and Opportunities
Challenges
- Expiration of patents could lead to biosimilar competition.
- Price sensitivity among payers and patients.
- Rapid innovation leading to new, more effective therapies.
Opportunities
- Expansion into new indications (e.g., gastric, bladder).
- Combination regimens increasing demand.
- Strategic partnerships and value-based contracts.
Key Takeaways
- NDC 62135-0883 (Tecentriq 1200 mg) has maintained a stable list price of ~$11,350 per dose since 2018.
- The global immuno-oncology market grows at double digits annually, with Tecentriq holding substantial market share.
- Pricing pressure is expected to increase over the next 3–5 years due to biosimilars and payer negotiations.
- Total treatment costs can exceed USD 130,000 annually, impacting market dynamics and reimbursement considerations.
- Market expansion into new indications and combinations presents growth opportunities despite competitive pressures.
FAQs
1. How does Tecentriq's price compare to competitors?
Tecentriq’s list price per dose is comparable to Keytruda, with Keytruda slightly higher at USD 12,500 per 200 mg. Actual pharmaceutical costs vary due to discounts and reimbursement contracts.
2. Will biosimilars reduce Tecentriq’s price significantly?
Yes. Biosimilars could reduce prices by 20%–30% when they enter the market, likely within the next 3–5 years, assuming regulatory approval and market adoption.
3. What factors influence Tecentriq’s pricing?
Regulatory approvals, competition, indications expansion, reimbursement policy, and biosimilar development influence pricing.
4. How does the treatment landscape affect Tecentriq’s market share?
Increased competition from other immunotherapies and combination regimens could dilute market share, unless Tecentriq expands into new indications or improves dosing protocols.
5. Are there regional differences in Tecentriq pricing?
Yes. Pricing varies widely due to national pricing policies, reimbursement, and healthcare system structures, with developed markets generally having higher list prices.
References
[1] MarketsandMarkets. (2022). Oncology immunotherapy market analysis.
[2] Centers for Medicare & Medicaid Services. (2023). Drug pricing and reimbursement policies.
[3] IQVIA. (2022). Global pharmaceutical pricing and market access report.
[4] FDA. (2019). Approval of atezolizumab (Tecentriq) for bladder cancer.
